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Follicular lymphomaBcl-2, the foundingmember of a family of apoptotic regulators, was initially identiﬁed as the protein product of a
gene that is translocated and overexpressed in greater than 85% of follicular lymphomas (FLs). Thirty years later
wenowunderstand that anti-apoptotic Bcl-2 familymembersmodulate the intrinsic apoptotic pathway by bind-
ing and neutralizing themitochondrial permeabilizers Bax and Bak aswell as a variety of pro-apoptotic proteins,
including the cellular stress sensors Bim, Bid, Puma, Bad, Bmf and Noxa. Despite extensive investigation of all of
these proteins, important questions remain. For example, howBax and Bak breach the outermitochondrialmem-
brane remains poorly understood. Likewise, how the functions of anti-apoptotic Bcl-2 family members such as
eponymous Bcl-2 are affected by phosphorylation or cancer-associatedmutations has been incompletely deﬁned.
Finally, whether Bcl-2 family members can be successfully targeted for therapeutic advantage is only now being
investigated in the clinic. Here we review recent advances in understanding Bcl-2 family biology and biochemis-
try that begin to address these questions.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Apoptosis is a distinct form of cell death initiated by various physio-
logical and pathological stimuli. Morphologically, apoptosis is charac-
terized by cell shrinkage followed by formation of cell fragments,
which are rapidly cleared by phagocytes that recognize “eatme” signals
on the plasma membrane [1–3]. Biochemically, apoptosis typically
involves the conversion of various signals into caspase-mediated intra-
cellular protease activity [1,2,4].
One of the two major pathways leading to apoptosis is the mito-
chondrial or intrinsic biochemical pathway [5,6]. The signature
biochemical change during activation of this pathway (Fig. 1) is the
leakage of cytochrome c into the cytoplasm [7], where it facilitates
caspase 9 activation to initiate a caspase cascade [1,3,8]. This release ofinase; AML, acutemyelogenous
ukemia; CR, complete response;
ma;MM,multiplemyeloma;PR,
ingle nucleotide variant; TM,
rch, Gonda 19-205,Mayo Clinic,
1 507 293 0107.
ufmann.Scott@Mayo.educytochrome c from mitochondria is regulated by members of the Bcl-2
protein family, which include three functionally and structurally
distinct subfamilies: i) pro-apoptotic effector proteins Bax and Bak,
which mediate mitochondrial outer membrane permeabilization
(MOMP); ii) anti-apoptotic family members, including Bcl-2, Bcl-xL,
Mcl-1, Bcl-w and A1, which antagonize MOMP; and iii) pro-apoptotic
BH3-only proteins, which promote apoptosis either directly by binding
and oligomerizing Bax and Bak or indirectly by neutralizing anti-
apoptotic family members [9–12]. When the balance between these
Bcl-2 family members tips in favor of cell death, Bax and Bak form olig-
omers that permeabilize the mitochondrial outer membrane (MOM),
resulting in release of cytochrome c and many other mitochondrial
intermembrane space proteins [13].
Apoptosis plays an essential role in development, immune response
and tissue homeostasis [14,15]. Moreover, dysregulation of apoptosis is
thought to play a critical role in degenerative diseases and cancer [16].
For example, genomic changes leading to overexpression of the anti-
apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 are observed in a variety of
neoplasms [17,18]; and genes encoding pro-apoptotic proteins such as
Bax and Bim aremutated or deleted in selected cancers [19,20]. Accord-
ingly, dysregulation of apoptosis – and particularly the intrinsic apopto-
tic pathway – is considered a hallmark of cancer [21].
Although the intrinsic pathway of apoptosis was broadly outlined
20 years ago [1,3], extensive progress over the past 3–4 years has pro-
vided new insight into its criticalmolecular processes. Structural studies
Fig. 1. Overview of the mitochondrial pathway [1,2,4]. The signature event of the mitochondrial or intrinsic death pathway is MOMP, which results in release of cytochrome c and other
mitochondrial intermembrane proteins to the cytoplasm [13]. Once in the cytoplasm, cytochrome c facilitates the interaction of the cytoplasmic scaffolding protein Apaf-1 and procaspase
9, activating a caspase cascade that leads to cleavage of hundreds to cellular caspase substrates to generate the apoptotic phenotype [3,4]. As described in the text, Bcl-2 family members
regulate this pathway upstream of MOMP. While Bax and Bak are directly responsible for breaching the outer membrane, their oligomerization and activation are modulated by other
family members. BH3-only proteins such as Puma, Bim, tBid, and Noxa, which are termed “activators,” transiently bind Bax or Bak [39], facilitating their activation. BH3-only proteins
such as Bad, which are unable to directly bind Bax or Bak, are termed “sensitizers” because they bind and neutralize anti-apoptotic Bcl-2 family members.
1659C. Correia et al. / Biochimica et Biophysica Acta 1853 (2015) 1658–1671of Bax and Bak have begun to illuminate their oligomerization and
function. Moreover, new understanding of anti-apoptotic Bcl-2 family
member regulation has emerged. Here we summarize these recent de-
velopments, focusing particularly on Bax/Bak activation and Bcl-2 regu-
lation. For more comprehensive reviews, readers are referred to [9–12].2. Advances in understanding Bax/Bak activation
2.1. Bax/Bak oligomerization: some answers, more questions
Despite the strong correlation between Bax/Bak oligomerization and
MOMP [22,23], mechanisms of Bax/Bak activation and MOMP remain
incompletely understood. Earlier studies showed that homo-
oligomerization of Bak and Bax requires their BH3 domains [24]. More
detailed mutagenesis and crosslinking assays implicated two interac-
tion interfaces in Bak oligomerization. One is a BH3 domain:BH3
binding groove interaction in which the BH3 domain (α2 helix) of one
Bak molecule interacts with the BH3 binding groove (α3–α5 helices)of another [25]. The second interface implicated in oligomerization in-
volves Bak α6 helices [26,27].
Several models have been advanced to account for Bak oligomeriza-
tion [26,27]. First, Bak monomers could form head-to-tail oligomers.
Along these lines, an octamer “asymmetric-single conformer” model
of oligomerization has been derived from molecular dynamic simula-
tions [28]. Alternatively, it has been proposed that Bak monomers
could form symmetric dimers, with the BH3 domain of one monomer
inserted into the BH3 binding groove of its partner and the opposite
face of each molecule in the dimer involved in protein–protein interac-
tions leading to higher order oligomerization [10,26]. A similar model
has been proposed for Bax [29]. One potential problem with models
based on symmetric dimers is that C-terminal transmembrane (TM) do-
mains of the two Bax or Bak monomers in each homodimer would face
in opposite directions, i.e., with one transmembrane domain pointed
into the membrane and the other oriented away from it. Nonetheless,
recent crystal structures of Bax or Bak fragments fused to EGFP (to
facilitate crystallization) provide strong evidence for symmetric dimers
[30,31]. Understanding in greater detail how assembly of these dimers
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the next major challenge in this area.
2.2. BH3-only proteins and Bax/Bak activation: direct activation, indirect
activation or both?
There is general agreement that formation of Bax or Bak oligomers
requires BH3-only proteins [32]. The exact role of the BH3-only proteins
in Bax/Bak oligomerization, however, has been contentious, with three
different models proposed.
According to the direct activation model, BH3-only proteins are di-
vided into direct activators and sensitizers [33–35]. Direct activators in-
clude Bim, Puma and tBid, which can directly bind to Bax and/or Bak to
induce their oligomerization [36–39]. Accordingly, Bid−/−Bim−/−
Puma−/− triple knockout mice show some of the same developmental
defects as Bax−/−/Bak−/− double knockout mice [40], although other
defects appear to be absent [41]. Moreover, Bim−/−Puma−/− double
knockout cells [42] and Bid−/−Bim−/−Puma−/− triple knockout cells
display extensive, albeit incomplete, resistance to most apoptotic stim-
uli, suggesting that these proteins play a predominant role in Bax/Bak
activation [40]. Although Bid and Bim can both activate Bax and Bak, it
has been reported that Bim preferentially activates Bax, while Bid pref-
erentially activates Bak [43].
In this model, the BH3-only protein Bad is a sensitizer, i.e., a protein
that neutralizes anti-apoptotic Bcl-2 family members to release activa-
tors, which subsequently induce apoptosis [34]. Consensus regarding
the role other BH3-only proteins has been more difﬁcult to achieve.
For example, while some studies have demonstrated direct activation
of Bak by Noxa protein [39,44], others have reported that Noxa BH3
peptide cannot directly activate Bax or Bak [30,31,45]. These different
results might reﬂect, in part, use of full-length protein in some studies
versus BH3 domain peptide in others.
Other aspects of BH3-only protein interactions with Bax or Bak also
remain unresolved. While transient binding of BH3-only proteins to the
canonical BH3 binding groove of Bax or Bak has been implicated in trig-
geringBax/Bak activation in some studies [30,31,39,46], a secondary site
for triggering Bax activation has been identiﬁed in others [37,47,48]. Be-
cause the peptide derivative used in the latter studies is much more ef-
fective than native Bim BH3 peptide in binding and activating Bax [49],
detection of the secondary site might reﬂect unique properties of the
ligand.
According to the alternative indirect activationmodel, themajor role
of BH3-only proteins is to neutralize anti-apoptotic Bcl-2 family mem-
bers, causing them to release Bax and Bak, which are then immediately
competent to permeabilize the MOM [50,51]. An earlier argument for
this model was the lack of direct evidence for complexes between
BH3-only proteins and Bax or Bak in intact cells [50]. However, interac-
tions between BH3-only family members and Bak are now known to be
transient [39,45]; and structural studies have also conﬁrmed interac-
tions between BH3-only proteins and Bax or Bak [30,31]. While the
indirect activation model has fallen out of favor, the possibility that
Bax and Bak are present in a preactivated state in cells – one of the pos-
tulates of this model – has not been fully explored and might have im-
portant implications for Bax and Bak function.
A more recent, uniﬁed model combines elements of both prior
models by suggesting that anti-apoptotic Bcl-2 family members inhibit
MOMP both by sequestering direct activators and by binding activated
Bax and Bak [52]. Consistent with this model, a number of biochemical
[38,53–55], cellular [56–58], and genetic [59] studies now agree that
anti-apoptotic Bcl-2 family members have dual functions in inhibiting
apoptosis.
2.3. Once activated, how do Bax and Bak permeabilize the MOM?
Once BH3-only proteins trigger oligomerization of Bax and/or Bak, it
is still unclear how MOMP occurs. Structural studies of Bcl-xL [60], Bax[61] and Bak [62] have revealed similarity between Bcl-2 family proteins
and channel-forming domains of bacterial toxins such as diphtheria
toxin [63] and colicin E1 [64], raising the possibility that all of these pro-
teins may utilize similar mechanisms to permeabilize membranes. By
analogy to the toxins,which are thought to insert their twohydrophobic
core domains as hairpins into membranes to form pore like struc-
tures [65], a “hairpin insertion model” has also been proposed for Bax
[66]. In particular, Bax α5 and α6, together with α9, are thought to in-
sert into the MOM, while the other α helices from different Bax mono-
mers interact to promote oligomerization at the MOM cytoplasmic
surface [66–69].
On the other hand, recent crystal structures of activated Bax and Bak
suggest that conformational changes during activation involve separa-
tion ofα5 andα6 rather than hairpin formation [30,31]. These observed
changes, which are thought to allow Bax and Bak to assume more ﬂex-
ible conformations, may resolve the issue of conﬂicting TM domain ori-
entation in the dimers described above. However, the observed crystal
structures are not consistent with models in which Bax or Bak inserts
hydrophobic hairpins into the MOM to form pores. Instead, based on
further results showing that some of the residues within the putative
α5/α6 hairpin label with membrane-impermeable reagents and others
do not, it has been suggested that α5 and α6 collapse onto the MOM
rather than inserting into it [70]. Whether this leads to MOMP through
disruption of membrane curvature [71,72] or another process still re-
mains to be determined.
2.4. Harnessing BH3-only protein biology to predict chemotherapeutic
response
Understanding the mitochondrial pathway has direct implications
for cancer therapy. Over the past 20 years, this pathway has been impli-
cated in the cytotoxicity of many chemotherapeutics [73,74], including
DNA damaging agents [75], spindle poisons [76,77], and kinase inhibi-
tors [78,79]. Conversely, chemotherapy resistant cancers often contain
mitochondrial pathway defects [80,81].
As described above, BH3-only proteins have been grouped into
“direct activators” and “sensitizers” [35,82]. “Priming of cells for
death” was originally deﬁned as a state in which addition of BH3 do-
mains from sensitizer BH3-only proteins to isolated mitochondria (an
assay termed “BH3 proﬁling”) results in robust cytochrome c release
[83]. This state was correlated with the presence of Bim bound to anti-
apoptotic Bcl-2 family proteins such as Bcl-2 or Mcl-1 as well as
simultaneous expression of Bax and/or Bak on theMOM [83].Moreover,
sensitivity to the Bcl-2/Bcl-xL antagonist ABT-737 correlated strongly
with release of cytochrome c by certain BH3 domain peptides, notably
Bad [83–85].
In further studies, BH3 proﬁling predicted cancer cell sensitivity to not
only BH3 mimetics, but also chemotherapeutic agents, particularly the
topoisomerase II inhibitors etoposide, daunorubicin and mitoxantrone
[86]. In contrast, this assay was less predictive of sensitivity to the nucle-
oside analogs cytarabine and clofarabine or the hypomethylating agents
azacitidine and decitabine [85–87].
The original cytochrome c release assay employed for BH3 proﬁling
has been replaced by a more efﬁcient cell-based JC-1 dye binding assay
[88] that measures loss of mitochondrial membrane potential [85,89,
90]. This JC-1 assay can be performed by ﬂow cytometry, which enables
examination of responses in phenotypically distinct cell types such as
leukemic myeloblasts or hematopoietic stem cells (HSCs) [86]. Interest-
ingly, this assay demonstrated that leukemic myeloblasts are more
highly primed and exhibit a pattern more suggestive of Bcl-2
dependence than HSCs [86,91], leading to a phase 2 trial of the Bcl-2 an-
tagonist ABT-199. For reasons that are still under investigation, the
assay predicted far better clinical activity than was actually observed
[92], raising the possibility that it might be better to assay the effects
of the BH3 mimetic drugs themselves rather than effects of naked syn-
thetic peptides. Before describing that trial, we ﬁrst review recent
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members.
3. Advances in understanding regulation of anti-apoptotic Bcl-2
family proteins
3.1. Structure and function: variations on a theme
Since the discovery of Bcl-2 [17,93,94] and its ability to promote tu-
morigenesis by inhibiting cell death [95], ﬁve structurally related anti-
apoptotic family members, including Bcl-xL, Mcl-1, Bcl-w, BFL1 (A1 in
mouse) and Bcl-B (Bcl2L10 in mouse), have been identiﬁed [10,11,96].
These share four conserved regions [Bcl-2 homology (BH) domains]
(Fig. 2). In addition, Bcl-2, Bcl-xL, Mcl-1, Bcl-w and Bcl-B all contain
C-terminal TM domains that direct them to intracellular membranes,
particularly the MOM. BFL1 lacks a classical TM but is targeted to mito-
chondria by its C-terminal α-helix [97–99], whereas the mouse homo-
log Bcl-2A1 appears in some studies to be cytoplasmic. All of these
proteins possess a remarkably similar globular structure containing a
so-called “Bcl-2 core” [11] consisting of eight α-helices oriented so
that helices 3, 4 and 5 form a hydrophobic groove that is capable of
binding the BH3 domains of pro-apoptotic family members.
Despite their similarity, anti-apoptotic Bcl-2 familymembers exhibit
speciﬁcity for various pro-apoptotic proteins [51,100]. Most of the anti-
apoptotic proteins bind most of the BH3-only family members, but
Bcl-xL and Bcl-w reportedly fail to bind Noxa; Bcl-2 does not bind trun-
cated Bid, Bik, Hrk or Noxa well; Mcl-1 does not interact with Bad, Bik
and Hrk; and BFL1/A1 fails to bind Bad and Bmf. Bcl-B, on the other
hand, only binds Bim and Bik. Likewise, all of the anti-apoptotic family
members bind Bax, but only Bcl-xL, Mcl-1, BFL1 [101,102] and in some
cases Bcl-2 [103] bind Bak.
The selectivity of these interactions, coupled with differences in ex-
pression of pro- and anti-apoptotic proteins under divers conditions, is
thought to underlie the variable responses of cells to assorted stresses
[36,83,101]. According to this view, Bcl-2, Bcl-xL and Bcl-w bind to al-
most all pro-apoptotic proteins and are more potent protectors than
Bcl-B, BFL1 and Mcl-1, which bind only a subset of the pro-apoptotic
proteins. On the other hand, several observations also argue against
this model. First, it has been observed thatMcl1 gene deletion is lethal
in a variety of cell lineages [104–109], although this might reﬂect an ob-
ligate role for Mcl-1 in oxidative phosphorylation within mitochondria
rather than its anti-apoptotic role on the surface mitochondria [106].
Moreover, recent results suggest that the relative potencies of these
proteins might reﬂect their relative expression levels rather than the
range of pro-apoptotic proteins neutralized [110].
3.2. The role of anti-apoptotic Bcl-2 family proteins in tumorigenesis
Apoptosis not only contributes to normal development and tissue
homeostasis, but also provides a barrier to cancer development. For
example, c-Myc provokes changes that induce not only proliferation,
but also apoptosis, limiting its ability to transform cells [81,111]. As aFig. 2. Bcl-2 phosphorylation. (A). Schematic representation of the Bcl-2 proteinwith BHdomain
and S87 are locatedwithin the FLD and selectively targeted for phosphorylation. S70 is phosphor
apoptotic function of Bcl-2 [54]. (B). Residues S62 and S64 (labeled in red)within the FLD of Bcl-
membrane domain.
Adapted from [54,154].result, Myc-induced transformation of lymphoid cells in vitro and
in vivo is augmented by overexpression of Bcl-2 [95,112] or Bcl-xL
[113]. Similar results in other neoplasms [114] have led to extensive ef-
forts to elucidate apoptotic pathway dysfunction in various cancers.
High Bcl-2 protein levels are detected in a variety of neoplasms, in-
cluding small cell lung, breast, prostate, colorectal, and bladder cancers,
melanoma, and especially human lymphoid malignancies [115–117].
Elevated Bcl-2 expression has also been reported in acute myeloid
leukemia (AML), particularly chemotherapy-resistant AML [118,119],
although this has not been universally observed [120].
As summarized in Table 1, manymechanisms contribute to the high
Bcl-2 levels observed in various neoplasms. First, the t(14,18) chromo-
some translocation that places the BCL2 gene next to immunoglobulin
heavy chain (IGH) enhancer elements [17,93,94] is a major mechanism
for elevated Bcl-2 transcription in lymphomas. Second, chromosome
deletions and mutations that result in loss of miR-15a and miR-16,
which target and repress Bcl-2mRNA, occur inmore than 50%of chronic
lymphocytic leukemia (CLL) cases [121]. Third, Bcl-2 levels are regulat-
ed by protein ubiquitination [122–124]. The inhibitor of NF-E2-related
factor 2 (INrf2) interacts with the BH2 domain of Bcl-2 and directs it
to Cul3-Rbx1-mediated ubiquitination. Accordingly, inactivating muta-
tions of INrf2 found in some lung cancer cell lines [124] can stabilize
Bcl-2 and confer resistance to apoptotic stimuli. Similar mechanisms,
i.e., genomic changes that enhance expression, altered regulation by
miRNAs, and diminished ubiquitin-mediated turnover, contribute to
upregulation of the other anti-apoptotic Bcl-2 family members in vari-
ous cancers as well (Table 1).3.3. Anti-apoptotic Bcl-2 family member phosphorylation
The anti-apoptotic functions of Bcl-2 and its kin are governed not
only by changes in expression, but also by phosphorylation. In particu-
lar, Bcl-2 is phosphorylated in response to a number of stimuli, includ-
ing spindle poisons such as paclitaxel, vincristine and vinblastine, as
well as serum starvation [125–128]. As summarized in Fig. 2, several
residues within the unstructured ﬂexible loop domain (FLD) of Bcl-2
are phosphorylated, including T56, T69, S70, T74, and S87 [122,
128–130]. Kinases implicated in these phosphorylations include c-Jun
N-terminal kinase (JNK) [131,132], c-Raf [127], protein kinase A [133],
p38 MAPK [134], PKCα [135], mTOR [136] and CDK1 [137,138]. Impor-
tantly, Bcl-2 is phosphorylated on several of these residues during
mitosis [139,140], suggesting a possible physiological role for Bcl-2
phosphorylation during cell division.
How phosphorylation affects Bcl-2 function has been somewhat
controversial. An S70A Bcl-2 variant protects cells from paclitaxel-
induced cell death better than wild type (wt) Bcl-2 does, suggesting
that S70 phosphorylation inhibits Bcl-2 function [141]. Likewise, Bcl-2
T69A/S70A/S87A affords enhanced protection from Ca2+-dependent
death stimuli [142]. However, phosphomimetic mutants with Glu in
place of T69, S70 and/or S87 also exhibit enhanced anti-apoptotic effects
[143–145], suggesting that phosphorylation activates Bcl-2.s boxed in blue and ﬂexible loop domain (FLD) labeled in gray. Residues T56, T69, S70, T74
ylated byCDK1 in vivo, inducing a conformation change of the FLD and enhancing the anti-
xL andMcl-1, respectively, are targeted for phosphorylation by CDK1 [137,154]. TM, trans-
Table 1
Mechanisms of antiapoptotic Bcl-2 family member dysregulation in cancer.
Bcl-2
family
member
Overexpressed in Genomic alterations miRNA loss E3 ubiquitin ligase loss Other mechanisms
Bcl-2 Lymphoid malignancies [115–117]
and melanoma [224] as well as
small cell lung [21,225], breast
[226],
prostate [227], colorectal [228]
and bladder cancers [229].
t(14;18)
chromosomal
translocation in
lymphomas [17,93,94]
Loss of miR-15a and miR-16 in
CLL [121]
Loss of miR-195, miR-24-2,
miR-365-2 and miR-204 in
breast, lung and colon cancer
[230,231]
Loss of INrf2 [124]
Bcl-xL Hormone-refractory prostate
cancer [232] and mesenchymal
breast cancer [233]
Gene ampliﬁcation,
often in concert with
c-Myc, in multiple
solid tumors [18]
Decrease miR-let7c in
hepatocellular and lung
cancers [234,235] as well as
AML [236]
Decreased miR-491-5P in
pancreatic [237], colorectal
[238], and ovarian cancer
[237].
Loss of phosphoglycerate
mutase 5, which is required
for binding to the E3
ligase INrf2 [124]
Stat5 activation by Bcr/abl
in CML [239]
Mcl-1 Relapsed acute leukemia [120],
CLL [240], multiple myeloma
[241–243] as well as breast [244],
ovarian [245], colorectal [246],
gastric [247], hepatocellular [248],
and non-small cell lung cancers [18].
Gene ampliﬁcation in
multiple solid tumors
[18]
Loss of miR-29 in many solid
tumors [249], miR-125b in
hepatocellular carcinoma
[250,251] or miR-133b in lung
cancer [252]
Increased expression of the
deubiquitinase USP9X in FL,
DLBCL and multiple myeloma
[250]
Mutation or loss of the E3
ubiquitin ligase FBW7 in a
variety of cancers [253,254]
NFκB-mediated transcription,
e.g., in large granular
lymphocytic leukemia [255]
Bcl-w Gastric [256,257] and colorectal
cancers [258] as well as
glioblastoma
multiforme [259,260].
Gene ampliﬁcation in
CML, ovarian and
colorectal cancers
[261,262]
Downregulation miR-125b
[251], miR-335 [263,264],
miR-497 [265], miR-203 [266]
or miR-122 [267]
Not known Enhanced promoter activity
by β-catenin/TGF4 signaling
in colorectal cancer [268].
BFL1 ALL, CLL and DLBL [269–272]. Not known Not known Regulated by ubiquitination.
No E3 ligase has been
identiﬁed [273,274].
Transcriptional activation by
NFκB [275],
e.g., downstream
of constitutive PI3K or ERK
activation [276,277] that
occurs in many solid tumors.
Bcl-B DLBL and breast, prostatic, gastric,
colorectal, and small cell lung
cancers [278]. High level associates
with poor prognosis.
Not known Not reported Ubiquitinated protein. No
E3 ligase has been
identiﬁed [279].
Not known
1662 C. Correia et al. / Biochimica et Biophysica Acta 1853 (2015) 1658–1671It was originally suggested that Bcl-2 phosphorylation might alter
binding of proteins such as p53 or c-Myc to the Bcl-2 FLD, therebymod-
ulating apoptosis [146,147]. However, the observation that FLD deletion
completely blocks paclitaxel-induced apoptosis [132] raised the possi-
bility that FLD modiﬁcations might modulate Bcl-2 function through a
process distinct from altering protein–protein interactions involving
the FLD. Consistent with this view, we recently found that mutation of
T69, S70, T74 or S87 to either Glu or Ala increases the afﬁnity of Bcl-2
for Bak and Bim [54], indicating that FLD modiﬁcations modulate Bcl-2
function through a process that does not require introduction of a neg-
ative charge. Moreover, we also observed altered protease sensitivity,
suggestive of a conformational change, aftermutation of Bcl-2 S70 to ei-
ther Glu or Ala [54]. During paclitaxel-induced mitotic arrest, Bcl-2 was
phosphorylated and more tightly bound to Bak and Bim. Collectively,
these results suggest that phosphorylation of the Bcl-2 FLD leads to a
conformational change in the “Bcl-2 core” that affects binding of pro-
apoptotic proteins to the BH3 binding groove.
Interpretation of these results would have been enhanced by struc-
tural information about the impact of FLD alterations on overall Bcl-2
conformation. Unfortunately, all published Bcl-2 structures either lack
the FLD or replace it with the corresponding region of Bcl-xL [148,149].
Phosphorylation also modulates the function of other anti-apoptotic
Bcl-2 family members. Bcl-xL is phosphorylated on T47 and S62 [150].
Phosphorylation of the latter site by JNK decreases binding of Bcl-xL to
Bax, thus diminishing Bcl-xL anti-apoptotic function [151]. Likewise,
Mcl-1 phosphorylation at S159 by glycogen synthase kinase-3 (GSK-3)
diminishes Mcl-1 anti-apoptotic function, in this case by enhancing
Mcl-1 binding to the ubiquitin E3 ligase βTrCP [152] and subsequent
turnover [153]. In contrast, CDK- and JNK-mediatedMcl-1 phosphoryla-
tion at S64 increases Mcl-1 binding to Noxa, Bak and Bim, therebypotentiating its anti-apoptotic activity [154]. Because phosphorylation
of Bcl-2 (on its FLD) and Mcl-1 (at S64) increases the anti-apoptotic ef-
fects of these proteins, it has been suggested that these phosphoryla-
tions might contribute to chemoresistance [155–157].
4. BCL2 sequence variation
4.1. BCL2 sequence variation in clinical lymphomas
As indicated above, BCL2 translocation to the IGH locus contributes
to high level Bcl-2 expression in 90% of FLs and 20% of de novo diffuse
large B-cell lymphomas (DLBCLs), mostly of the germinal center B-cell
subtype [158]. Some of these lymphomas also contain BCL2mutations.
Single nucleotide variants (SNVs), including some that cause amino
acid substitutions and others that are silent, were demonstrated soon
after BCL2was cloned [159,160]. Detection of similar SNVs in untreated
FL ruled out chemotherapy as a cause of these BCL2mutations [159]. In
contrast to the impact of other abnormalities involving BCL2, e.g., the
extremely poor prognosis of so-called “double hit” lymphomas that har-
bor translocations involving both theMYC and BCL2 genes [161], the ef-
fects of BCL2 SNVs on DLBCL and FL have been less clear.
Recent sequencing of large numbers of primary DLBCL samples and
matched germline DNA has demonstrated a high incidence of tumor-
associated BCL2 mutations and linked these changes to somatic
hypermutation, an activation-induced cytidine deaminase- (AID-) driv-
en mutagenic process that ordinarily generates antibody diversity
[162–165]. Becausemost BCL2mutations in DLBCL (60–90%) are synon-
ymous [162] and not associatedwith any impact on chemosensitivity or
survival [165], it has been assumed that BCL2 mutations in DLBCL are
passenger mutations.
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lent than DLBCL, FL nonetheless carries a 2–3%/year risk of transforma-
tion to a more aggressive neoplasm. Transformed FL (tFL) most often
resembles DLBCL morphologically [166,167] but historically has been
quite resistant to therapy [167,168]. This poor therapeutic response of
tFL has provided the impetus for recent genomic comparisons of un-
transformed and transformed FLs [169–171]. These analyses have dem-
onstrated that BCL2 is mutated, at least to some extent, in the majority
of FLs and tFLs [169–171]. Analysis of subclonal heterogeneity has sug-
gested that tFL arises from the original mutant FL clone, but not always
through linear progression of the clone that predominates during the
indolent phase of the disease. Instead, FL transformation commonly
reﬂects divergent evolution from a commonmutated ancestor, with in-
dependent acquisition of further aberrations in the indolent FL clone
and the more aggressive tFL [166,170].
4.2. Some BCL2 variants exhibit gain of function
Because BCL2 sequence variants inhibit cell death [172] and facilitate
lymphomagenesis [173], it has been assumed that BCL2mutations do
not affect Bcl-2 protein function. Our recent studies question this
assumption. In particular, we have observed that some variant Bcl-2
proteins from lymphoma cell lines exhibit enhanced activity [103,
174]. For example, the D31H/A60V Bcl-2 variant from the BCL2-
translocated lymphoma line RL binds Noxa 20-fold more tightly than
wildtype Bcl-2 and provides increased protection from the proteasome
inhibitor bortezomib, which upregulates Noxa to kill lymphoma cells
[174]. These observations prompted us to examinewhether BCL2muta-
tions in clinical lymphoma might also impact Bcl-2 function.
To address this issue, we compared the incidence, nature, and clini-
cal implications of BCL2mutations in a number of lymphoid neoplasms
[175]. In contrast to DLBCL, where most mutations are silent, a vast ex-
cess of amino acid altering (nonsynonymous) variants was observed in
FL. Moreover, the presence of BCL2mutations at diagnosis was an inde-
pendent prognostic factor that correlated with increased risk of deathFig. 3.Distribution of Bcl-2 amino acid substitutions in FL. (A). Schematic representation of the B
Somatic variants detected in FL derived from 2 independent cohorts (black and green bars) are
terations, with purple for synonymous, white for nonsynonymous with no charge introduction
with positive charge introduction. TM, transmembrane domain (adapted from Correia et al. [17
phoid cell lines (adapted from Dai et al. [103]). † indicates undetectable binding. (C). Kaplan M
(n= 128) (adapted from Correia et al. [175]).due to lymphoma [175]. The sequence context of the BCL2 mutations
in FL suggested that AID is responsible for these mutations. Consistent
with this conclusion, high AID levels in FLwere associatedwith a higher
probability of BCL2mutation at diagnosis and a shorter interval before
transformation [175].
In FL, amino acid altering mutations are spread along the Bcl-2 pro-
tein [165,175], with the highest frequency in the FLD (Fig. 3), a region
implicated in regulating afﬁnity of Bcl-2 for pro-apoptotic Bcl-2 family
members [54] as described above. Consistent with earlier studies in
lymphoma cell lines [103,174], preliminary analysis demonstrated
that some variant Bcl-2 proteins identiﬁed in FL exhibit increased ability
to bind and sequester the pro-apoptotic Bcl-2 family members Bim and
Puma [175]. Further analysis of additional variant proteins is needed to
determine the prevalence of BCL2 gain of function mutations in this
region.
FL-associated mutations also occur in other regions of Bcl-2 (Fig. 3).
For example, several mutations alter the BH4 domain, a region partially
conserved in Bcl-xL, Bcl-w, BFL1 and Bcl-B [10,176]. The implications of
these BH4 domain mutations are currently unknown. Although multi-
ple studies have reported that deletion of the BH4 domain abrogates
Bcl-2 anti-apoptotic function [177–179], the underlying mechanism
has been unclear. It has been suggested that BH4 domain deletion abro-
gates Bcl-2 heterodimerization with Bax [178]. Consistent with this
view, binding of a stapled BH4 peptide to a unique site on Bax has re-
cently been reported [180]. Other studies, however, have found no im-
pact of BH4 deletion on binding of Bcl-2 to Bax, Bak, Bad, Bik or Bim
[177]. Accordingly, further work is required to clarify the function of
the Bcl-2 BH4 domain and assess the impact of FL-associated mutations
in this region.
Comparison of sequential FL biopsies revealed a 4-fold increase in
frequency of overtly detectable BCL2mutations at transformation com-
pared to the same patients at diagnosis [175], suggesting that mutagen-
esis is ongoing in FL during the course of disease.Mutations identiﬁed at
transformation had a lower frequency of classical AID signatures, possi-
bly reﬂecting AID-induced mutation of cytidines outside the context ofcl-2 proteinwith BHdomains boxed in blue and ﬂexible loopdomain (FLD) labeled in gray.
distributed throughout the Bcl-2 protein. Color-coded symbols depict distinct types of al-
, red for nonsynonymous with negative charge introduction, and blue for nonsynonymous
5]). (B). Afﬁnities of Bak BH3 peptide and Bak protein for Bcl-2 variants derived from lym-
eier plots showing the impact of BCL2mutations on death due to lymphoma in a FL cohort
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tions were clearly nonfunctional, e.g., a BCL2 variant with a premature
stop codon [175], again emphasizing that not all BCL2 mutations en-
hance Bcl-2 function.
In accord with studies showing that FL transformation is genetically
complex and heterogeneous [166,169–171], BCL2mutations can suffer
several fates during the course of FL. In cases where there is a linear
evolution from an original malignant clone, BCL2 mutations would
be maintained throughout the course of the disease, perhaps with
the acquisition of additional alterations in the same mutant gene
over time. In cases where clones that give rise to the indolent FL
and tFL follow divergent paths from a common precursor, mutations
present in the dominant clone at diagnosis might not predominate
at transformation, where new genetic alterations that confer a
stronger proliferation or survival advantage could instead emerge.
Conversely, in clones that lack BCL2 mutations initially, BCL2 muta-
tions might emerge at transformation, as reported in our cohort
[175]. Whether these are driver or passenger mutations remains to
be determined.
In comparing recent studies of BCL2mutations in FL [169–171,175],
several important methodological differences must be kept in mind.
First, most of the studies were designed to identify all mutations in
the BCL2 locus. These studies not only sequenced the BCL2 promoter
and extensive intronic regions in addition to exons, but also counted
BCL2 as mutated even when a relatively small percentage of the reads
were variant, e.g., as few as three reads out of 85 [169]. In contrast,
our recent study, which involved Sanger sequencing of the protein cod-
ing exons, was designed to identifymutations that are i) present in pre-
dominant clones and ii) capable of altering Bcl-2 protein sequence and
function [175].
Second, the studies comprehensively examining genomic changes in
FL at transformation relied on the availability of paired FL pathological
samples. In contrast, in order to assess the relationship between FL
mutations, AID expression and clinical outcome, our recent study re-
lied on a prospectively maintained clinical database and relatively
uniform treatment practices at a single institution [175]. To have
enough events for survival analysis, however, the vast majority of
samples in our study predated the introduction of the anti-CD20 an-
tibody rituximab into clinical FL treatment [182]. Retrospective anal-
yses from the pre-rituximab era have reported a median survival of
only 1–2 years after FL transformation [167,168], whereas recent stud-
ies suggest improved survival with tFL in the rituximab era [166,183],
raising the possibility that rituximab might partially counter the ad-
verse impact of genomic changes leading to transformation. Thus, it
will be important in the future to assess whether BCL2mutation statusTable 2
Selective list of BH3 mimetics.
Agent Target BH3 mim
A-124077 Mcl-1 Authent
ABT-737 Bcl-xL, Bcl-2, Bcl-w Authent
ABT-263 (Navitoclax) Bcl-xL, Bcl-2, Bcl-w Authent
ABT-199 Bcl-2 Authent
GX15-070 (obatoclax) Bcl-xL, Bcl-2, Bcl-w, Mcl-1 Putative
Gossypol Bcl-2, Bcl-xL, Mcl-1 Putative
Apogossypolone (ApoG2) Bcl-xL, Bcl-2, Mcl-1 Putative
TW37 Bcl-xL, Bcl-2, Mcl-1 Putative
AT-101 Bcl-xL, Bcl-2, Mcl-1 Putative
a BH3 mimetic status deﬁned as in [186].
b Most advanced clinical testing reported at https://clinicaltrials.gov/.
c Abbreviations used are: NA, not applicable (no clinical testing); Ph, phase.
d Randomized Ph2 study of navitoclax + rituximab vs. rituximab alone in CLL.
e Ph3 study of ABT-199 + rituximab vs. bendamustine + rituximab for CLL.
f Ph2 studies in acutemyelogenous leukemia, small cell lung cancer (with topotecan or carbo
myeloma (with bortezomib) and non-small cell lung cancer (with docetaxel).
g Ph2 studies in chronic lymphocytic leukemia (with rituximab), hormone-resistant prostat
non-small cell lung cancer (with docetaxel), small cell lung cancer (alone or with topotecan),correlates with outcome in FL treated with rituximab-containing
chemoimmunotherapy.
5. Targeting Bcl-2 as an anticancer strategy
5.1. Small molecule inhibitors of Bcl-2 family proteins
Because Bcl-2 overexpression contributes to the pathogenesis of var-
ious lymphoid neoplasms, particularly FL and CLL [17,93,94,121], and
possibly solid tumors [80], there has been substantial effort to develop
Bcl-2 inhibitors as therapeutic agents. A combination of nuclear mag-
netic resonance-based binding assays andﬂuorescence polarization dis-
placement assays [184,185] has identiﬁed a number of small molecules
that interfere with protein–protein interactions involving the Bcl-2,
Bcl-xL and/or Mcl-1 BH3 binding grooves [10,11,186–189], thus
mimicking the effects of sensitizer BH3-only proteins depicted in
Fig. 1.
For a small molecule to truly be a BH3 mimetic, its killing must de-
pend on Bax and/or Bak, it must have a high afﬁnity for at least one
anti-apoptotic Bcl-2 family member, and it must induce cytotoxicity
that correlates with binding to anti-apoptotic protein(s) [186]. Some
compounds originally reported to be BH3 mimetics, e.g., BH3I class
compounds, HA14-1, antimycin A, and purpurogallin, are no longer
thought to kill in this manner because they exhibit poor binding to
BH3 binding grooves or Bax/Bak-independent killing [186,190,191].
Other agents (Table 2) meet the criteria outlined above and have
undergone preclinical and, in some cases, clinical testing. These include
AT-101 [the R-(-)-enantiomer of gossypol] [192–194]; the gossypol de-
rivatives TW37 [192], apogossypol, and apogossypolone (ApoG2) [195,
196]; and obatoclax (GX15-070) [186,197–199], although obatoclax
also kills Bax/Bak-deﬁcient cells [191,200], perhaps because it inhibits
the pro-survival kinase mTOR [201].
Of particular note are ABT-737 and its orally bioavailable derivative
ABT-263 (navitoclax). These agents bind the BH3 binding grooves of
Bcl-xL, Bcl-2, and Bcl-w [186,191,192,202–204] to kill cells in a Bax- or
Bak-dependent manner [191,192]. Interestingly, their major toxicity,
thrombocytopenia, also results from Bcl-xL inhibition [205,206]. To
avoid this side effect, the Bcl-2-selective derivative ABT-199 has been
developed [207]. Cellular studies have shown that ABT-737, navitoclax
and ABT-199 displace Bim from their identiﬁed anti-apoptotic binding
partner(s), facilitating Bax-mediated MOMP [203,208,209]. Priming of
Bcl-2with the activator Bim increases sensitivity to ABT-737, navitoclax
and ABT-199, whereas Mcl-1 overexpression favors resistance [56,191,
203,208–210]. All of these observations are consistent with the pro-
posed mode of action of these agents.etic statusa Clinical statusb References
ic NAc [188]
ic NA [186,191,192,202,204]
ic Ph2d [203]
ic Ph3e [208,280]
/off-target effects Ph2f [197]
/off-target effects NA [184,281]
/off-target effects NA [195]
/off-target effects NA [186,192,282]
/off-target effects Ph2g [192,193,280]
platin/etoposide),mantle cell lymphoma (with bortezomib), Hodgkin lymphoma,multiple
e cancer (with prednisone/docetaxel), diffuse large B cell lymphoma (with lenalidomide),
and glioblastoma (alone or with radiation).
Table 3
Summary of selected current ABT-199 clinical trials.
Disease Clinical characteristics or eligibility Regimens Phase Ref.a
AMLb Treatment naïve age ≥ 65 ineligible for standard chemotherapy ABT-199 + Decitabine or + Azacitidine Ib
AML Treatment naïve ABT-199 + Cytarabine I/II
AML NA ABT-199 II [92]
B-cell NHL, DLBCL NA ABT-199 + rituximab or oblinutuzumab + CHOP
CLL R/R or treatment naïve ABT-199 + oblinutuzumab Ib [221]
CLL R/R or treatment naïve ABT-199 + bendamustine + rituximab Ib [222]
CLL, NHL R/R ABT-199 I [219]
CLL, SLL R/R ABT-199 + rituximab Ib [220]
CLL R/R to B-cell receptor inhibitor ABT-199 II
CLL, 17p deletion R/R ABT-199 II
CLL R/R ABT-199 + rituximab or + bendamustine and rituximab III
FL R/R ABT-199 + rituximab or + bendamustine and rituximab II
MM Treatment with Bortezomib and dexamethasone ABT-199 I
MM R/R ABT-199 I
NHL, MM R/R ABT-199 I
NHL R/R ABT-199 + bendamustine + rituximab Ib [223]
a References for ABT-199 trials that have been reported in abstract form.
b Abbreviations: AML, acute myeloid leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell
lymphoma; FL, follicular lymphoma; NA, not available; NHL, Non-Hodgkin's lymphoma; MM, multiple myeloma; R/R, relapsed/refractory; and SLL, small lymphocytic leukemia.
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In view of the important role of Bcl-2 in the pathogenesis of
lymphoid malignancies (see above), BH3 mimetics have been exten-
sively tested in these disorders (reviewed in [211]). Early clinical testing
revealed activity of navitoclax in CLL and non-Hodgkin's lymphoma
(NHL) [212,213]. With the development of ABT-199, studies of
navitoclax continue in solid tumors, where it is being used to target
Bcl-xL, whereas studies in Bcl-2-dependent hematological malignancies
have focused more extensively on ABT-199.
As of January 2015, 16 clinical trials testing ABT-199 either as a single
agent or in combination therapy (www.clinicaltrials.gov) are ongoing. A
variety of neoplasms are being studied, including CLL, aggressive NHL,
FL, multiple myeloma (MM) and AML (Table 3). In preclinical studies,
anti-tumor activity of ABT-199 has also been reported in T-cell ALL,
chronic myelogenous leukemia, and colorectal and breast cancers
[214–217].
Early clinical results suggest that ABT-199 has promising activity in
relapsed or refractory (R/R) lymphoid malignancies. In particular,
ABT-199 has an overall response rate (ORR) of 56% in R/R NHL [218]
and 84% (20% complete response) in R/R CLL and small lymphocytic
leukemia (SLL) [219]. Indeed, responses in CLL and SLL have been so
brisk that tumor lysis syndrome has been a major complication of
therapy. In contrast, despite tantalizing activity against AML cells
ex vivo [91], ABT-199 has showndisappointing activity (12.5% complete
remission rate) in R/R AML [92], perhaps because of elevated Mcl-1 in
this setting [120].
Additional studies are investigating ABT-199 in combination with
other therapies (Table 3). For example, Roberts et al. reported an 86%
ORR (31% CR) in R/R CLL treated with ABT-199 and the anti-CD20 anti-
body rituximab [220]. Other studies in R/R or untreated CLL patients
combined ABT-199 with obinutuzumab, a glycoengineered anti-CD20
antibody [221], or in CLL and NHL with bendamustine/rituximab
[222,223]. More mature reports of these promising investigations
are awaited with interest.6. An agenda for the future
Despite improvements in understanding signaling through the
intrinsic apoptotic pathway over the past 2–3 years, important ques-
tions remain. Recent studies have clariﬁed how BH3-only proteins
induce Bax or Bak activation and provided detailed descriptions of
Bax and Bak homodimers, but these results provide limited insight
into the mechanism by which Bax and Bak breach the MOM. Furtherstudies of higher order Bax and Bak oligomers, perhaps in the
presence of appropriate lipids, are required for progress in this area.
Even though the Bcl-2 protein was identiﬁed almost 30 years ago,
important questions about its structure and function persist. How phos-
phorylations in the FLD affect afﬁnity of the BH3 binding groove for its
ligands is entirely unclear. While recent studies suggest that changes
in the FLD can affect Bcl-2 conformation [54], an NMR or crystal struc-
ture of Bcl-2 with its own loop intact is required to better understand
this aspect of Bcl-2 regulation.
The consequences of nonsynonymous BCL2mutations also require
further investigation. While these mutations become more prevalent
during the course of FL [175], it is unclear whether they are driving FL
transformation or are merely bystanders that reﬂect high AID activity
in FLs at highest risk of transformation. Further study is also required
to determine which BCL2 mutations affect Bcl-2 protein function and
how these amino acid changes, whether in the FLD or elsewhere, alter
afﬁnity of the BH3 binding groove.
Finally, a number of questions need to be answered to assure the op-
timal clinical development of ABT-199. In hematological malignancies,
this agent currently appears to be most active in CLL, a disease driven
by overexpression of wt Bcl-2. Whether the BCL2mutations observed
in FL will affect ABT-199 sensitivity remains to be determined. Further-
more, it is presently unclear whether ABT-199 will be as active in dis-
eases where Bcl-2 overexpression, while present, plays a less clear-cut
role in pathogenesis (e.g., small cell lung cancer). Finally, additional
work is required to identify optimal combinations that capitalize on
the promising single-agent activity of ABT-199 observed to date.
Given the recent exciting advances, continued investigation of these
questions appears warranted.
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